Clinical Trial Update: Alectinib in Neo-adjuvant Treatment of Stage III NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating neoadjuvant alectinib for stage III non-small cell lung cancer. The study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alecensa (alectinib)

Snippet

Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING